2017
Targeting ATR in cancer medicine
Sundar R, Brown J, Russo A, Yap T. Targeting ATR in cancer medicine. Current Problems In Cancer 2017, 41: 302-315. PMID: 28662958, DOI: 10.1016/j.currproblcancer.2017.05.002.Peer-Reviewed Original ResearchPoly(ADP-ribose) polymerase inhibitorsATR inhibitorsDNA damage responsePolymerase inhibitorsEarly-phase clinical trialsAtaxia telangiectasiaImmune checkpoint inhibitorsBiomarkers of responseCheckpoint inhibitorsDNA damagePreclinical dataCombinatorial regimensPatient selectionReplication-associated DNA damageAntitumor strategyCell cycle checkpoint signalingClinical developmentRepair of replication-associated DNA damagePreclinical biologyTargeting ATRAntitumor therapyATR inhibitionSingle agentCell cycle checkpointsClinical trialsAdvances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
Dolly S, Collins D, Sundar R, Popat S, Yap T. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs 2017, 77: 813-827. PMID: 28378229, DOI: 10.1007/s40265-017-0732-2.Peer-Reviewed Original ResearchConceptsAnaplastic lymphoma kinaseEpidermal growth factor receptorDevelopment of molecular-targeted agentsAdvent of immune checkpoint inhibitorsNon-small-cell lung cancerPredictive biomarkers of responseEmergence of acquired resistanceTreatment approachesAdvanced NSCLC patientsImmune checkpoint inhibitorsProgression-free survivalMolecular targeted agentsBiomarkers of responseNon-small-cellTreatment of patientsCancer-related mortalityGrowth factor receptorMutation-specific inhibitorsAnti-tumor agentsCheckpoint inhibitorsNSCLC patientsGene aberrationsDownstream signaling blockadePredictive biomarkersMolecular subtypes
2016
Emerging biomarkers for PD-1 pathway cancer therapy
Lim J, Sundar R, Chnard-Poirier M, Lopez J, Yap T. Emerging biomarkers for PD-1 pathway cancer therapy. Biomarkers In Medicine 2016, 11: 53-67. PMID: 27936870, DOI: 10.2217/bmm-2016-0228.Peer-Reviewed Original ResearchConceptsPD-L1Predictive biomarkers of responseImmune checkpoint inhibitorsImmune-related toxicitiesPD-L1 expressionPD-L1 inhibitorsBiomarkers of responseTreatment response biomarkersMultiple tumor typesIntermediate end pointsCheckpoint inhibitorsPD-1Predictive biomarkersImmuno-oncologyResponse assessmentTumor typesResponse biomarkersCancer therapyEnd pointsTherapy designBiomarkersFDA registrationTreatmentInhibitorsDifferential responding